Document Detail

Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study.
MedLine Citation:
PMID:  22429268     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To determine whether postoperative subconjunctival bevacizumab significantly alters bleb vascularity.
DESIGN: A randomized, prospective interventional study.
PARTICIPANTS: Forty-three eyes from 39 patients were recruited, with 21 eyes randomized to subconjunctival injections of 5-fluorouracil, and 22 eyes to combined 5-fluorouracil/bevacizumab.
METHODS: All patients who underwent uncomplicated primary antimetabolite augmented trabeculectomy who subsequently required postoperative subconjunctival 5-fluorouracil injection within 4 weeks of surgery were eligible. Patients were randomized to receive subconjunctival 5-fluorouracil only (7.5 mg/0.15 mL) or 5-fluorouracil plus bevacizumab (1.25 mg/0.05 mL).
MAIN OUTCOME MEASURES: Primary outcome was bleb vascularity with secondary endpoints including visual acuity, intraocular pressure, bleb morphology, complications and total numbers of 5-fluorouracil injections were recorded at baseline, week 12 and 18 months.
RESULTS: At week 12, there was no significant difference between groups for visual acuity, intraocular pressure, bleb vascularity and morphology, or total number of 5-fluorouracil injections. By 18 months, 47.4% of the 5-fluorouracil/bevacizumab group exhibited central bleb avascularity compared with 21.1% of the 5-fluorouracil group (Fisher's exact test, P = 0.17). Two bleb complications (one blebitis; one suture abscess) recorded in the 5-fluorouracil/bevacizumab group.
CONCLUSIONS: After a single combined injection, a trend for increased central bleb avascularity was observed, although this effect was not sufficient to reach statistical significance. This, in addition to the occurrence of two bleb-related complications in the bevacizumab group, suggests the need for a larger clinical trial to further evaluate the safety and efficacy of bevacizumab as a modulating agent in glaucoma filtration surgery.
Brian E Chua; Dan Q Nguyen; Queena Qin; Jonathan B Ruddle; Anthony P Wells; Nuwan Niyadurupola; Viney Gupta; Tina T Wong; Michael A Coote; Jonathan G Crowston
Related Documents :
22819398 - Postoperative infection rates in low risk patients undergoing percutaneous nephrolithot...
22639298 - Comparative study of spinopelvic sagittal alignment between patients with and without d...
22831808 - Preoperative intravascular balloon catheters and surgical outcomes in pregnancies compl...
20952228 - Prevention of relapse following intraoral vertical ramus osteotomy mandibular setback: ...
19120528 - Discarding antimicrobial prophylaxis for transurethral resection of bladder tumor: a fe...
21923418 - A randomized controlled trial comparing the efficacy of hybrid bipolar transurethral va...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-06-04
Journal Detail:
Title:  Clinical & experimental ophthalmology     Volume:  40     ISSN:  1442-9071     ISO Abbreviation:  Clin. Experiment. Ophthalmol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-03-17     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100896531     Medline TA:  Clin Experiment Ophthalmol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  773-9     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists.
Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, and Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antimetabolites / therapeutic use*
Conjunctiva / drug effects
Drug Therapy, Combination
Fluorouracil / therapeutic use*
Glaucoma / surgery*
Intraocular Pressure / physiology
Middle Aged
Pilot Projects
Prospective Studies
Surgical Flaps / blood supply*
Tonometry, Ocular
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Wound Healing / drug effects
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Antimetabolites; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 51-21-8/Fluorouracil
Comment In:
Clin Experiment Ophthalmol. 2012 Nov;40(8):769-70   [PMID:  23134427 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unmyelinated nerve fibers in the human dental pulp express markers for myelinated fibers and show so...
Next Document:  Predictors of seizures during pregnancy in women with epilepsy.